Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Furans
  • Ketones

abstract

  • Eribulin demonstrated activity with manageable tolerability (including infrequent grade 3 and no grade 4 neuropathy) in heavily pretreated patients with MBC when dosed as a short IV infusion on days 1 and 8 of a 21-day cycle.

publication date

  • June 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.17.7618

PubMed ID

  • 19349550

Additional Document Info

start page

  • 2954

end page

  • 61

volume

  • 27

number

  • 18